CN110913851B - 治疗外伤性脑损伤的组合物和方法 - Google Patents

治疗外伤性脑损伤的组合物和方法 Download PDF

Info

Publication number
CN110913851B
CN110913851B CN201880040029.9A CN201880040029A CN110913851B CN 110913851 B CN110913851 B CN 110913851B CN 201880040029 A CN201880040029 A CN 201880040029A CN 110913851 B CN110913851 B CN 110913851B
Authority
CN
China
Prior art keywords
tbi
compound
alkyl
group
cmx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201880040029.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN110913851A (zh
Inventor
A·巴古斯
R·贝乌威克斯
R·卡塞莱
D·A·小德沃尔
S·A·凯特
A·S·拉德尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ischemix
Original Assignee
Ischemix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ischemix filed Critical Ischemix
Publication of CN110913851A publication Critical patent/CN110913851A/zh
Application granted granted Critical
Publication of CN110913851B publication Critical patent/CN110913851B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880040029.9A 2017-04-25 2018-04-25 治疗外伤性脑损伤的组合物和方法 Expired - Fee Related CN110913851B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762489735P 2017-04-25 2017-04-25
US62/489,735 2017-04-25
PCT/US2018/029372 WO2018200680A1 (en) 2017-04-25 2018-04-25 Compositions and methods for treating traumatic brain injury

Publications (2)

Publication Number Publication Date
CN110913851A CN110913851A (zh) 2020-03-24
CN110913851B true CN110913851B (zh) 2023-08-25

Family

ID=62148517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880040029.9A Expired - Fee Related CN110913851B (zh) 2017-04-25 2018-04-25 治疗外伤性脑损伤的组合物和方法

Country Status (9)

Country Link
US (3) US10744115B2 (https=)
EP (2) EP4282411A1 (https=)
JP (2) JP7203756B2 (https=)
CN (1) CN110913851B (https=)
AU (2) AU2018258158A1 (https=)
CA (1) CA3061203A1 (https=)
DK (1) DK3615023T3 (https=)
ES (1) ES2952834T3 (https=)
WO (1) WO2018200680A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018258158A1 (en) * 2017-04-25 2019-11-21 Ischemix Llc Compositions and methods for treating traumatic brain injury
US20240124520A1 (en) * 2019-10-16 2024-04-18 The Board Of Trustees Of The Leland Stanford Junior University N-acylated histidine dipeptides as anticancer agents
CN116199666B (zh) * 2023-03-07 2025-02-28 中国药科大学 两亲性化合物及其药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802622A (zh) * 2009-05-14 2012-11-28 艾雪米克斯公司 用于治疗缺血和缺血再灌注损伤的组合物和方法

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1047991B (de) 1957-11-20 1958-12-31 Nordmark Werke Gmbh Verfahren zur Herstellung chemisch stabiler, untoxischer, steriler Injektionsloesungen von Thioctsaeure
US3875207A (en) 1967-01-25 1975-04-01 Ciba Geigy Corp Process for the temporary protection of amino groups in peptide syntheses
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
CA1219824A (en) 1981-04-17 1987-03-31 David C. Ward Modified nucleotides and methods of preparing and using same
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5288706A (en) 1987-12-25 1994-02-22 Mitsui Toatsu Chemicals, Incorporated Medicament for prevention and remedy of diseases of the pancreas and others
US5039660A (en) 1988-03-02 1991-08-13 Endocon, Inc. Partially fused peptide pellet
FR2653334B1 (fr) 1989-10-19 1991-12-20 Erphar Ste Civile Preparation cosmetique de bronzage.
DE59010810D1 (de) 1989-11-09 1998-04-16 Asta Medica Ag Arzneimittel enthaltend als Wirkstoff R-alpha-Liponsäure oder S-alpha-Liponsäure
DE4000397A1 (de) 1990-01-09 1991-07-11 Hoechst Ag Lipidselektive antioxidantien sowie deren herstellung und verwendung
CA2118496C (en) 1992-04-24 2005-01-11 Roger Randall Charles New Method of reducing microorganism adhesion
DE4235912C2 (de) 1992-10-23 2002-12-05 Viatris Gmbh Verfahren zur Herstellung kristalliner Thioctsäure und deren Verwendung
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
WO1997000889A1 (en) 1995-06-21 1997-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Peptides binding to low-density lipoproteins
JPH0990542A (ja) 1995-09-28 1997-04-04 Konica Corp ハロゲン化銀写真感光材料
FR2741075B1 (fr) 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques, leur utilisation a titre de medicament et compositions les contenant
CA2264485A1 (en) 1996-09-06 1998-03-12 St. Elizabeth's Medical Center Of Boston, Inc. Gata-6 transcription factor: compositions and methods
IL123887A0 (en) 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
JPH117099A (ja) 1997-06-13 1999-01-12 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
US6090842A (en) 1998-03-10 2000-07-18 The Regents Of The University Of California Lipoic acid analogs
DE19834608A1 (de) 1998-07-31 2000-02-03 Basf Ag Kristallmodifikation der Liponsäure
JP2000169371A (ja) 1998-10-02 2000-06-20 Sankyo Co Ltd ジチオラン誘導体を含有する医薬
EP1133317A1 (de) 1998-11-26 2001-09-19 Pentapharm AG Transportsystemkonjugate
US7214658B2 (en) 2004-07-06 2007-05-08 Tact Ip, Llc Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
WO2001009118A2 (en) 1999-07-29 2001-02-08 Patrick T Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
CA2389429C (en) 1999-11-18 2012-05-29 Victor E. Shashoua Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6890896B1 (en) 1999-11-18 2005-05-10 Ceremedix, Inc. Compositions and methods for counteracting effects of reactive oxygen species and free radicals
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
WO2001080851A1 (en) * 2000-04-21 2001-11-01 United States Army Medical Research And Materiel Command Method of treating, preventing or inhibiting central nervous system injuries and diseases
JP2002189271A (ja) 2000-12-21 2002-07-05 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料およびその処理方法
EP1371640B1 (en) 2001-03-19 2009-10-28 Senju Pharmaceutical Co., Ltd. Novel a-lipoic acid derivative and use thereof
JP2005515156A (ja) 2001-05-25 2005-05-26 セレメディックス，インク． 反応性酸素種およびフリーラジカルの効力を中和するための単一アミノ酸に基づく化合物
JP4259813B2 (ja) 2001-05-29 2009-04-30 千寿製薬株式会社 α−リポイルアミノ酸の安定化法および安定化されたα−リポイルアミノ酸を含有する水性液剤
DE10163836A1 (de) 2001-12-22 2003-07-10 Friz Biochem Gmbh Multifunktionales Reagenz zur Synthese von thiolmodifizierten Oligomeren
WO2003055853A1 (en) 2001-12-26 2003-07-10 Nippon Soda Co., Ltd. Electron-accepting compounds capable of forming self-assembled monolayers
AUPS065102A0 (en) 2002-02-20 2002-03-14 Unisearch Limited Fluorous acetalation
EP1476440A4 (en) 2002-02-22 2005-06-01 Albany College Of Pharmacy METHODS AND COMPOUNDS USEFUL IN INHIBITION BY RADICAL AND / OR OXIDIZING AGGRESSION AND IN THE TREATMENT AND PREVENTION OF DISEASE
JP2003286168A (ja) 2002-03-28 2003-10-07 Senju Pharmaceut Co Ltd α−リポイルアミノ酸を含有する皮膚外用剤
JP4376540B2 (ja) 2002-05-31 2009-12-02 アイバイツ株式会社 金属表面修飾剤および新規含硫黄化合物
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
TWI331034B (en) 2002-07-08 2010-10-01 Piramal Life Sciences Ltd Inhibitors of cyclin-dependent kinases and their use
CA2492807A1 (en) 2002-07-29 2004-03-04 Nanodel Technologies Gmbh Nanoparticles for dna administration to a target organ
US8603345B2 (en) 2003-02-13 2013-12-10 Becton, Dickinson And Company Devices for component removal during blood collection, and uses thereof
EP1454627A1 (en) 2003-03-06 2004-09-08 MyoContract Ltd. Alpha-Keto carbonyl calpain inhibitors
US20040204340A1 (en) 2003-04-11 2004-10-14 Guilford Pharmaceuticals, Inc. Polyprolyl inhibitors of cyclophilin
US7202270B2 (en) 2003-06-20 2007-04-10 Sami Labs Limited Convenient stable non-hygroscopic crystalline solid forms of racemic and chiral LA-plus salts: process for their manufacture and uses
WO2005063732A1 (en) 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma
EP1726596A4 (en) 2004-02-18 2009-08-26 Japan Science & Tech Agency SUGAR CHAIN LIGAND COMPOSITE COMPOUND AND PROCESS FOR PROTEIN ANALYSIS WITH THE LIGAND COMPOSITE COMPOUND
JP2006022066A (ja) 2004-07-09 2006-01-26 Shiseido Co Ltd 重合抑制剤および即時型黒化防止用皮膚外用剤
WO2006101909A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Combination therapy for treating or preventing diseases
WO2006101910A2 (en) 2005-03-16 2006-09-28 Ischemix, Inc. Peptide compounds and methods of using peptide compounds to treat conditions affecting the cardiac, pulmonary, and nervous systems
JP2008174453A (ja) 2005-04-28 2008-07-31 Iwaki Kk 頭皮脱毛治療剤
US8507439B2 (en) * 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
JP4951226B2 (ja) 2005-09-08 2012-06-13 立山化成株式会社 α−リポ酸アルカリ塩の製法
WO2007030581A2 (en) 2005-09-09 2007-03-15 Oregon Health & Science University Neuroprotectants
DE602006013787D1 (de) 2006-03-28 2010-06-02 Epitech Group Srl Eine Pharmazeutische Zusammensetzung zur Behandlung von Pathologien, die durch die allgemeine Immunantwort verursacht werden
US20080051691A1 (en) 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
JP2012508165A (ja) 2008-11-07 2012-04-05 イスティテュート ビオキーミコ ナッツィオナーレ サーヴィオ エスアールエル α−リポ酸誘導体及び薬物製剤へのそれらの使用
US8080674B2 (en) 2009-06-12 2011-12-20 Ampac Fine Chemicals Llc. Preparation of polymer-free R-(+)-α-lipoic acid magnesium salt
EP2821405B1 (en) 2009-06-15 2016-04-13 Encore Health, LLC Choline esters for treating presbyopia and cataract
EP3069612A3 (en) 2009-06-15 2016-10-19 Encore Health, LLC Dithiol compounds, derivatives, and uses therefor
IT1397154B1 (it) 2010-01-04 2013-01-04 Ghelardini Composti ad efficacia sia analgesica che antiperalgesica.
DK2640423T3 (en) 2010-11-18 2017-10-02 Ischemix Llc LIPOYL COMPOUNDS AND THEIR USE IN TREATMENT OF ISchemic DAMAGE
US20150329519A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations Comprising Lipoyl Compounds
WO2015174948A1 (en) 2014-05-14 2015-11-19 Ischemix, LLC Formulations comprising lipoyl compounds
AU2018258158A1 (en) * 2017-04-25 2019-11-21 Ischemix Llc Compositions and methods for treating traumatic brain injury

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102802622A (zh) * 2009-05-14 2012-11-28 艾雪米克斯公司 用于治疗缺血和缺血再灌注损伤的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Salidroside Improves Behavioral and Histological Outcomes and Reduces Apoptosis via PI3K/Akt Signaling after Experimental Traumatic Brain Injury;Szu-Fu Chen等;《PLOS ONE》;20120930;第7卷(第9期);第1-15页 *

Also Published As

Publication number Publication date
AU2024202147A1 (en) 2024-05-02
AU2018258158A1 (en) 2019-11-21
JP7203756B2 (ja) 2023-01-13
JP2023030158A (ja) 2023-03-07
CN110913851A (zh) 2020-03-24
US11213509B2 (en) 2022-01-04
WO2018200680A1 (en) 2018-11-01
US10744115B2 (en) 2020-08-18
EP3615023A1 (en) 2020-03-04
DK3615023T3 (da) 2023-09-25
US20220280477A1 (en) 2022-09-08
EP3615023B1 (en) 2023-06-21
ES2952834T3 (es) 2023-11-06
EP4282411A1 (en) 2023-11-29
JP2020517731A (ja) 2020-06-18
CA3061203A1 (en) 2018-11-01
US20200352904A1 (en) 2020-11-12
US20180303796A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
ES2728948T3 (es) Tratamiento de la inflamación cerebral usando Fenilacetato de L-Ornitina
US8093262B2 (en) Use of huperzine for disorders
JP2023030158A (ja) 外傷性脳傷害を治療するための組成物および方法
ES2393933T3 (es) Conjugados que comprenden un fármaco psicotrópico o un agonista GABA y un ácido orgánico y su uso para el tratamiento del dolor y otros transtornos del SNC
CN102216257B (zh) Gaba偶联物及其使用方法
ES2743153T3 (es) Métodos para tratar el síndrome de fibromialgia
ES2952727T3 (es) Tratamiento de la enfermedad de Alzheimer en una población de pacientes particular
JP6837835B2 (ja) トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療
CN102985085A (zh) 治疗双相型障碍的方法
ES2698363T3 (es) Composiciones de oxprenolol para tratar el cáncer
US12144815B2 (en) Use of aprepitant for treating Alzheimer's disease
ES2385702T3 (es) Antagonistas de A2A para uso en el tratamiento de trastornos de la motricidad
EP3270889B1 (en) Targeted liposomal delivery of cgmp analogues
ES2725893T3 (es) Composiciones enriquecidas con S-enantiómeros de betabloqueantes para tratar la esclerosis lateral amiotrófica
JP2008514733A (ja) 標的化プロテアーゼインヒビターによる、外傷性もしくは変性性の神経疾患、耳科疾患または眼科疾患の処置
ES2414861T3 (es) Uso del FTS para el tratamiento de trastornos malignos
EP2982382A1 (en) Compounds for preventing ototoxicity
HK40016595A (en) Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
HK40016595B (en) Lipoyl-glu-ala for the treatment of neurodegenerative damage caused by traumatic brain injury
US20200323797A1 (en) Treatment of Obesity-related Conditions
HK40102267A (zh) 用於治疗孤独症谱系障碍(asd)的方法
WO2013044123A1 (en) Uses of bis(3)-cognitin and related compounds
CN111166868A (zh) 一种用于治疗神经疾病和障碍的组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20230825